A gene therapy conference unveiled that an immune cell therapy, led by HIV specialists from the University of California, San Francisco (UCSF) and developed by the non-profit CaringCross, has successfully maintained viral suppression for up to nearly two years in individuals with early-stage HIV infection. This breakthrough is considered a significant proof-of-concept in the pursuit of a "functional cure." The therapy utilizes genetically modified autologous T cells derived from patients, establishing a dual "attack + defense" mechanism. After seven participants received a single infusion of these modified cells and discontinued their conventional medications, three individuals with early infection maintained undetectable viral loads for 92 and 48 weeks, respectively. Another participant exhibited partial viral suppression within 12 weeks. However, the three patients with longer-established infections did not achieve sustained efficacy, likely due to more entrenched viral reservoirs and more severe immune system damage, which necessitated the resumption of drug therapy. The study indicates that early intervention can curb the expansion of the viral reservoir, preserve more robust immune function, and facilitate the modified cells' ability to re-establish antiviral defenses. Despite the small sample size, the 100% viral control observed in early-stage patients provides vital evidence of the therapy's potential effectiveness.